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Growth in the number of active patients on the kid-
ney transplant waiting list has slowed. Projections
based on the most recent 5-year data suggest the to-
tal waiting list will grow at a rate of 4138 registra-
tions per year, whereas the active waiting list will in-
crease at less than one-sixth that rate, or 663 regis-
trations per year. The last 5 years have seen a small
trend toward improved unadjusted allograft survival
for living and deceased donor kidneys. Since 2004 the
overall number of pancreas transplants has declined.
Among pancreas recipients, those with simultaneous
kidney-pancreas transplants experienced the highest
pancreas graft survival rates.
In response to the ongoing shortage of deceased donor
organs, the US Health Resources and Services Admin-
istration launched the Organ Donation Breakthrough
Collaborative in September 2003 and the Organ Trans-
plantation Breakthrough Collaborative (OTBC) in Octo-
ber 2005. The 58 DSA Challenge is prominent among
the goals adopted by the OTBC. Its premise: were each
of the 58 existing donation service areas to increase the
number of kidney transplants performed within their
boundaries by 10 per month, an additional 7000 trans-
plants over current annual levels would result. Such an
increase could potentially eliminate the national kid-
ney transplantation waiting list by 2030.
Key words: Deceased donor kidneys, 58 DSA Chal-
lenge, donation service areas, expanded criteria
donors, 7000 Kidney Challenge, kidney transplanta-
tion, living donor transplantation, OPTN, Organ Dona-
tion Breakthrough Collaborative, organ procurement
organization, Organ Transplantation Breakthrough
Collaborative, pancreas transplantation, SRTR, sur-
vival
Introduction
The first two sections of this article will review recent
trends in kidney and pancreas transplant waiting list ac-
tivity, transplant rates and outcomes. New to this year’s
report are figures covering trends in active and inactive
kidney waiting list status. Previous policies of the Organ
Procurement and Transplantation Network (OPTN) allowed
accrual of waiting time during the first 30 days of Status 7
(inactive status) designation, only. However, in November
2003, the OPTN implemented a new policy that permits
accrual of waiting time during the entire period that a pa-
tient remains in Status 7. This modification in OPTN policy
appears to have precipitated a marked change in transplant
center practice, resulting in much smaller growth in the ac-
tive kidney transplant waiting list than had previously been
expected.
Concurrent with this reduction in the rate of growth of the
active kidney transplant waiting list, the Health Resources
and Services Administration (HRSA) launched the Break-
through Collaborative initiatives in September 2003, which
seek among other objectives to reduce the gap between
the size of the transplant waiting list and the deceased
donor pool by improving consent rates and the utilization
of deceased donor organs. The third section of this article
will present the rationale behind the 58 DSA Challenge, a
bold initiative, first proposed as the 7000 Kidney Challenge
and adopted by the Organ Transplant Breakthrough Collab-
orative (OTBC), to increase the transplantation of kidneys
from all donor sources. The goal of the 58 DSA Challenge
is to reduce the kidney transplant waiting list to zero by
2030.
Kidney Transplantation
Kidney transplant waiting list trends
Over the past 10 years, the annual number of kid-
ney transplants performed nationally grew by 44%, from
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11 561 transplants in 1997 to 16 646 transplants in 2006.
During this same timeframe, the national OPTN kidney
transplant waiting list has grown linearly. Figure 1 demon-
strates this trend, showing the period prevalence counts
(candidates alive at any time during the year), point preva-
lence counts (candidates alive on the waiting list on De-
cember 31 of each year) and new candidate counts by year
from 1997 to 2006. During this decade, perhaps reflect-
ing the increased prevalence of end-stage renal disease
(ESRD) (1), the total number of candidates on the kidney
transplant waiting list at any time during the calendar year
increased by 81%, from 49 208 to 88 877, while the total
number of patients on the kidney waiting list at year-end
rose by more than 88% from 35 526 to 66 961. Growth
in the number of wait-listed patients has been accompa-
nied by a more than doubling of deaths on the waiting list
from 2184 in 1997 to 4456 in 2006. The increase in the
number of waiting list deaths perhaps reflects the effects
of a combination of influences, including an increase in
waiting list size, longer waiting times for deceased donor
transplantation, more liberal wait-listing standards and an
increasing average age of wait-listed kidney transplant can-
didates. Support for the theory that an increase in waiting
list size contributed to the increase in the number of wait-
ing list deaths is found in the concurrent decrease in the
annual death rate for waiting list candidates from a high
of 84 deaths per 1000 patient-years at risk in 1999 to 70
deaths per 1000 patient-years at risk in 2006. During the
same period, the annual death rate for waiting list candi-
dates age 50–64 years dropped from 99.6 deaths to 80.4
deaths, while the death rate for candidates age 65+ years
dropped from 150 to 113. Most notably, the death rate for
waiting list candidates with diabetes dropped from 148.9
in 1999 to 102.4 in 2006.
Although the overall numbers of candidates on the wait-
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Source: 2007 OPTN/SRTR Annual Report, Tables 1.3, 5.2, 5.3
Figure 1: Number of new and prevalent kidney waiting list
candidates and deaths on the waiting list, 1997 to 2006.




















Figure 2: Active status kidney waiting list patients at year-
end, 1997–2006.
tients on the waiting list has changed little since 2001. In
fact, the most recent increases in the size of the overall
waiting list largely reflect an increase in Status 7 listings
(Figure 2). The number of active patients, 31 662 on 31
December 1997, rose to 44 265 at the end of 2002. How-
ever, by the end of 2006, only an additional 2989 patients
had been added to the active candidate list, bringing the
total number of active candidates on 31 December 2006
to 47 254. In contrast, the number of inactive patients on
the kidney transplant waiting list increased slowly from
3864 candidates at year-end in 1997 to 6064 candidates
in 2002 and then more than tripled to 19 707 patients by
31 December 2006.
Among the possible explanations for the increased use of
Status 7 by transplant centers is a change in OPTN pol-
icy implemented in November 2003 that provides for the
accrual of waiting time during the entire interval that wait-
listed candidates are designated as inactive. Prior to this
policy change, candidates ceased accruing waiting time
after remaining in Status 7 for 30 days, and further waiting
time accrual resumed only after the Status 7 designation
was removed. It is possible that removal of this restriction
has led to more candidates being designated as Status 7
when they suffer adverse changes in their health status.
It is additionally possible that some of this increase in the
use of Status 7 may reflect a change in the demographics
of the waiting list, specifically the increasing age and mor-
bidity of wait-listed candidates. However, it may be that
this change in policy has encouraged the practice of listing
patients in Status 7 prior to completing their evaluation and
activating them when their pre-transplant evaluation is
complete. This latter explanation is supported by the data
shown in Table 1 documenting an increase in the percent-
age of candidates who are placed into Status 7 at the
time they are registered on the kidney transplant waiting
list. In 2003, 11% of inactive candidates were designated
as being in Status 7 at the time of wait-listing. By 2006,
that percentage had increased to 44%. The cumulative
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Table 1: Distribution of time to first inactive status among inactive registrants, 2002–2006
Time to inactive status (N%)
Year of Number of
inactive status inactive registrants At listing 1–90 days after listing 91+ days after listing
2002 5059 603 12% 668 13% 3788 75%
2003 6445 680 11% 848 13% 4917 76%
2004 10192 2525 25% 1186 12% 6481 63%
2005 10485 3720 35% 1298 12% 5467 52%
2006 10571 4666 44% 1427 14% 4478 42%
Source: SRTR Analysis, August 2007.
probability of becoming active was calculated for these
inactive patients. Among candidates who were inactive
at waitlisting before the policy change, 83% became ac-
tive or received a living donor transplant after 1 year, while
among candidates who were listed in Status 7 after the
policy change, 78% became active or received a living
donor transplant after 1 year (SRTR analysis, December
2007).
The proportion of the active kidney transplant waiting list
over the age of 50 years has increased during the past
decade from 42% to 57% (Table 2). This shift in the age
distribution of the waiting list reflects changes in the rates
of wait-listing of the different age groups. Wait-listing for
candidates under 50 years of age declined in recent years,
while growth in the new listings has been almost exclu-
sively among candidates aged 50 years or older. The num-
ber of active candidates younger than 50 years of age grew
from 18 550 in 1997 to 21 114 in 2002 but then decreased
to 20391 by 2006. The number of active candidates over
age 50 rose from 13 112 in 1997 to 23 151 in 2002 to 26 863
in 2006. In contrast, the number of inactive candidates
younger than 50 years increased from 2042 in 1997 to
2749 in 2002, and then to 7815 by 2006; the number of
inactive candidates over 50 years grew from 1822 in 1997
to 3315 in 2002 and then to 11 892 in 2006 (SRTR analysis,
May 2007).
Table 2: Annual number and distribution of kidney waiting list patients by patient characteristic and status at year-end, 1997–2006
Active Inactive
Characteristic 1997 2002 2006 1997 2002 2006
N 31 662 44 265 47 254 3864 6064 19 707
<35 years 21% 16% 13% 17% 13% 12%
35–49 years 38% 32% 30% 36% 33% 28%
50–64 years 34% 40% 42% 37% 40% 43%
65+ years 8% 12% 15% 11% 14% 17%
White 44% 40% 38% 48% 44% 39%
African American 36% 36% 34% 38% 40% 39%
Hispanic/Latino 12% 15% 18% 10% 11% 16%
Asian 6% 7% 8% 3% 3% 5%
Other/multi-race 1% 1% 1% 1% 2% 2%
Glomerular diseases 24% 23% 21% 22% 21% 19%
Diabetes 24% 25% 28% 25% 26% 29%
Hypertensive nephrosclerosis 15% 20% 21% 11% 18% 21%
Other 37% 33% 29% 42% 36% 31%
Source: Table 5.1a and SRTR Analysis, May 2007.
The distribution of race among candidates active on the
kidney waiting list has also evolved over the past 10 years
(Table 2). The number of white and African American ac-
tive candidates grew, respectively, from 14 048 in 1997 to
18 148 in 2006 and from 11 339 to 16 056. The distribution
of white candidates on the active waiting list has declined
from 44% to 38% and the distribution of African Ameri-
can candidates has decreased slightly from 36% to 34%.
In contrast, the total number of active Hispanic/Latino can-
didates more than doubled from 3910 in 1997 to 8560 in
2006, and Asian candidates increased from 1954 to 3828.
This has been reflected by an increase in the percentage
representation of those latter groups on the active waiting
list, as well.
The distribution of the diagnoses (glomerular diseases,
hypertensive glomerulosclerosis, diabetes and other
diseases) of candidates on the active kidney waiting list
has evolved over the past 10 years (Table 2). Overall, the
percentage of candidates with diabetes and hypertension
has increased from 24% to 28% and from 15% to 21%,
respectively, whereas the percentage with glomerular dis-
ease has declined from 24% to 21%. In 2006, the dis-
tribution of diagnoses was similar between those can-
didates who were active on the waiting list and those
who were in Status 7. Thus, it does not appear that
the increased fractions of listed diabetic and hypertensive
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candidates are driving the increase in the use of the Status
7 designation.
The median time to transplant for new candidates has
ranged around 1100 to 1200 days between 1998 and 2003
(the most recent year for which median times to trans-
plant may be calculated). During the same time period, the
median time to transplant for candidates age 50–64 years
ranged from 1277 to 1416 days. In 2002, the median time
to transplant for white candidates was 769 days, while the
median waiting time for all other races was over 1300 days.
Kidney donation and transplant trends
At the end of 2005, 97 556 patients had a functioning kid-
ney transplant compared with 60 427 in 1997, an increase
of 61%. The annual number of deceased donor transplants
rose 37%, from 7774 transplants in 1997 to 10 659 trans-
plants in 2006. The number of standard criteria donor (SCD)
transplants, expanded criteria donor (ECD) transplants and
transplanted kidneys recovered through donation after car-
diac death (DCD) grew by 22%, 59% and 684%, respec-
tively, during this same time interval (Figure 3). Despite the
higher percentile rates of growth among ECD and DCD
transplants, the greatest numerical increment compared
with 2002 has been in SCD transplants, with a gain of
984 SCD, 530 ECD (includes ECD/DCD), and 606 DCD.
Although the percentage of SCD kidneys allocated to can-
didates age <50 years has declined from 69% in 1997 to
49% in 2006, these candidates continue to receive SCD
kidneys at higher rates than their proportion on the waiting
list, which was 53% in 1997 and 40% in 2006.
Most of the growth (25%) in deceased donor kidney trans-
plantation since 2002 is driven by an increase in con-
version rates. This rate is defined as the number of de-
ceased donors meeting eligibility criteria (aged 0–70 years
with neurological death) divided by the number of eligi-
ble deaths (any ventilated death reported by a hospital
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Discard Rates
HRSA Collaboratives began in April 2003 
Figure 4: Average conversion and discard rates for all OPOs,
2002–2006.
ments). Among all donation service areas (DSAs), the aver-
age conversion rate grew from 48% in 2002 to 65% in 2006
(Figure 4). In contrast, the counterbalancing average dis-
card rate was 13% in 2002 and 16% in 2006.
There were 6434 living donor kidney transplants in 2006.
This represents a 64% increase in the number of liv-
ing donor transplants compared with 1997. Trends in liv-
ing related and living unrelated kidney donors are shown
in Figure 5. The number of living-related kidney donors
grew from 3224 in 1997 to a peak of 4349 in 2001.
Since then, the number of living related donors has
decreased to 3952 in 2006. From 1997 to 2006, the num-
ber of living unrelated kidney donors grew steadily from
655 to 2312. However, it appears that the rate of growth in
the living unrelated donor population has also slowed over
the past 2 years.
Kidney transplant patient and allograft survival trends
For single kidney transplants (multi-organ transplants ex-




















Source: 2007 OPTN/SRTR Annual Report, Table 5.4c
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Figure 5: Trends in living-related and living-unrelated donors,
1997–2006.


























Living Donor non-ECD ECD
Source: 2007 OPTN/SRTR Annual Report, Tables 5.14a, b, c .
Figure 6: Unadjusted 1-year, 3-year, and 5-year kidney recipi-
ent survival, by donor type: 2000–2005.
patient survival was best for recipients of living donor kid-
neys, intermediate for non-ECD deceased donor recipients
and lowest for those receiving ECD kidneys (Figure 6). Un-
adjusted patient survival rates at 5 years were 90% for re-
cipients of living donor kidneys, 83% for non-ECD kidneys
and 69% for ECD transplants (Table 3).
Kidney allograft survival follows the same pattern as that
seen for recipient survival (Figure 7). Graft survivals were
best for recipients of living donor kidneys, intermediate for
non-ECD transplants and lowest for ECD transplants. At
5 years, the unadjusted graft survival rate was 80% for liv-
ing donor, 70% for non-ECD and 55% for ECD transplants
(Table 3). Although kidney transplant patient survival per-
centages were not different when the first 5 years of the
decade under consideration were compared with the sec-
ond half (all p > 0.05), there is a significant trend toward
improvement in allograft survival (all p < 0.05).
Pancreas Transplantation
Pancreas transplant waiting list trends
The number of pancreata recovered in 2006 increased by
53% compared with 1997. However, there were approx-
imately 4000 people waiting for pancreas transplants at
the end of 2006, which is more than double the number in
1997, indicating a growing discrepancy between the num-
Table 3: Unadjusted graft and patient survival at 5 years among
deceased donor (non-ECD and ECD) and living donor kidney trans-
plant recipients, 1994–1999 and 2000–2005
Graft survival Patient survival
Donor type 1994–1999 2000–2005 1994–1999 2000–2005
Living donor 79.0% 80.2% 90.2% 90.3%
Non-ECD 67.6% 69.8% 82.7% 82.8%
ECD 51.0% 55.1% 70.9% 69.4%
























Living Donor non-ECD ECD
Source: 2007 OPTN/SRTR Annual Report, Tables 5.10a, b, c .
*Death is included as an event.
Figure 7: Unadjusted 1-year, 3-year, and 5-year kidney graft
survival,∗ by donor type: 2000–2005.
ber of candidates wait-listed for pancreas transplantation
and organs available. Corresponding to this is an increase
in waiting times for all types of pancreas candidates. The
median waiting time for a pancreas after kidney (PAK) trans-
plant has increased from about 220 days for candidates on
the list in the late 1990s to 562 days for candidates placed
on the list in 2004. The median waiting time for a simulta-
neous kidney-pancreas (SPK) transplant has risen from 380
days in 1997 to 451 days in 2005. The greatest growth over
the past decade in wait-listed patients has been among
those waiting for a PAK transplant (563%) or a pancreas
transplant alone (PTA) (166%); in contrast, the number of
SPK transplant candidates increased by ‘only’ 58%.
It is notable, however, that there have been recent down-
ward trends in SPK, PAK and total pancreas transplant reg-
istrations (Figure 8). The total number of new pancreas
waiting list registrations grew from 1740 in 1997 to a high
of 2796 in 2000, and then fell to 2548 by 2006. Only PTA
registrations showed a consistent increase from 1997 to




















SPK PAK PTA All Pancreas
Source: 2007 OPTN/SRTR Annual Report, Tables 6.2, 7.2, 8.2.
Figure 8: New registrations on pancreas waiting list, by trans-
plant type, 1995–2004.
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Source: 2007 OPTN/SRTR Annual Report, Tables 6.4, 7.4, 8.4.
Figure 9: Pancreas transplants, by transplant type, 1997–
2006.
registrations rose from 141 new registrations in 1997 to
a high of 623 in 2004, falling to 473 in 2006. New SPK reg-
istrations rose from 1412 in 1997 to a high of 2007 in 2000
and then declined to 1671 in 2006.
Pancreas transplant trends
The overall number of pancreas transplants rose from 1062
in 1997 to 1483 in 2004 and has since declined to 1386
(Figure 9). The number of SPK transplants peaked in 1998
and the number of PAK transplants in 2004. The prepon-
derance of pancreas transplants are SPK, accounting for
67% of all pancreas transplants in 2006.
Despite these trends toward fewer pancreas transplants
and waiting list registrations, the total number of people
alive with a functioning pancreas allograft increased 92%,
from 4670 in 1997 to 8984 in 2005 (Figure 10). The largest
relative increases occurred in the PAK and PTA popula-
tions, which experienced 5-fold and 4-fold increases, re-















Figure 10: Number of recipients living with a functioning pan-

























Source: 2007 OPTN/SRTR Annual Report, Table 1.13.
Figure 11: Unadjusted 1-year, 3-year, 5-year and 10-year pan-
creas patient survival, by transplant type.
spectively. Nonetheless, SPK recipients represent by far
the largest cohort of patients alive with a functioning pan-
creas allograft.
Pancreas transplant patient and allograft
survival trends
Patient survival rates were similar for PAK, SPK and PTA
recipients at 1 year (ranging from 95% to 97%), 3 years
(ranging from 91% to 92%) and 5 years (ranging from 84%
to 88%) (Figure 11). But, the 10-year patient survival rate
was lowest for PAK recipients at 64% and similar for SPK
and PTA recipients, with rates of 70% and 71%, respec-
tively.
Among pancreas recipients, those with SPK transplants
experienced the best pancreas graft survival rates: 86% at
1 year and 54% at 10 years (Figure 12). Graft survival rates
for PAK and PTA recipients were similar to one another,
with 1-year rates of 79% and 80%, respectively, and 10-

























Source: 2007 OPTN/SRTR Annual Report, Table 1.13.
*Death is included as an event.
Figure 12: Unadjusted 1-year, 3-year, 5-year and 10-year pan-
creas graft survival,∗ by transplant type.






































































Source: 2007 OPTN/SRTR Annual Report, Tables 1.3 and 5.1a. Predicted values for 2007-





Figure 13: Projected growth in the total and active waiting
list for deceased donor kidneys.
The National Organ Donation Breakthrough
Collaborative, the National Organ
Transplantation Breakthrough Collaborative
and the 58 DSA Challenge
Over the past decade, the number of kidney donations
from living and deceased donor sources has not kept pace
with growth in the total national kidney transplant waiting
list. However, since 2003, the growth in the waiting list
has been primarily among inactive (Status 7) candidates
(Figure 2). Figure 13 projects growth of the kidney trans-
plant waiting list, based upon 10-year and 5-year trends.
The projected yearly growth for active and total wait-listed
patients and for deceased and living donor transplants is
summarized in Table 4. From projections based upon the
most recent 5-year data, the total waiting list is estimated
to grow at a rate of 4138 registrations per year, whereas
the active waiting list is projected to increase at less than
one-sixth that rate, or 663 registrations per year (Figure 13).
The projected growth in the number of living and deceased
donor kidney transplants is shown in Figure 14 and Table 4.
Projections based on 10-year data suggest an increase in
the rate of living donor transplantations of 305 per year,
while the 5-year trend is considerably smaller, with growth
projected at only 49 incremental living donors per year.
Figure 14 and Table 4 also demonstrate the impact of re-
cent changes in DSA practices on deceased donor trans-
Table 4: Projected yearly growth of the kidney transplant total and
active waiting lists and of deceased and living donor transplants,
based on 10-year (1997–2006) and 5-year (2002–2006) trends
Projected yearly growth based on
Measure 10-year trend 5-year trend
Total on waiting list 3355 4138
Active waiting list 1710 663
Living donor transplants 305 49
Deceased donor transplants 289 549






















































Source: 2007 OPTN/SRTR Annual Report, Table 1.1. Predicted values for 2007-2020 based on 
slopes of the lines from 1997-2006 (long-dashed line) and 2002-2006 (short-dashed). DD (dark 
















Figure 14: Projected growth in living and deceased kidney
transplants, 1997–2020.
plant rates. The number of deceased donor transplants
is projected to increase by 289 per year based on the
10-year trend, but by 549 per year based on the most recent
5-year experience. Taken together, these data suggest that,
should current trends continue, the gap between the com-
bined living and deceased kidney transplantation rates and
the growth in the active waiting list is narrowing (Table 4).
In response to the ongoing shortage of deceased donor or-
gans, HRSA launched the National Organ Donation Break-
through Collaborative in September 2003 with the goal
of increasing national donation conversion rates to 75%
(Figure 4). Recognizing that opportunities to increase the
pool of available organs extend beyond increasing conver-
sion rates, a second round of the Collaborative, the Na-
tional Organ Transplantation Breakthrough Collaborative,
was convened in October 2005 with the objective of in-
creasing the average number of organs transplanted per
donor to 3.75. Underpinning the Collaborative strategy is
the belief that generating the will to change a specific
health care system requires the adoption of ambitious ob-
jectives that can only be achieved by implementing dra-
matic or ’breakthrough’ improvements (2). Therefore, the
Breakthrough Collaboratives have focused on developing
consensus around ’stretch goals’ that render existing work
processes inadequate and require that new systems be
implemented for targets to be achieved (2). Additionally,
the Collaborative built a framework through which best
practices can be shared among DSAs, both during and
between the formal Breakthrough Collaborative Learning
Sessions.
Among the innovations promoted by Collaborative par-
ticipants are the practices of placing in-house coordina-
tors (trained requestors) in large donor hospitals and the
involvement of critical care specialists (intensivists) to
establish well-defined goals and processes for the man-
agement of potential deceased donors (3,4). In addition, es-
tablishment of donor and recipient DCD and ECD selection
criteria have been shown to be effective in increasing uti-
lization of such donor organs. DCD outcomes from donors
952 American Journal of Transplantation 2008; 8 (Part 2): 946–957















The Expected Donation Rate is the rate expected based on national experience for OPOs serving similar donation service 
areas and hospitals. The Expected Donation Rate is adjusted for the following characteristics: Level 1 or 2 trauma center, 
Metropolitan Statistical Area size, CMS Case Mix Index, total bed size, number of ICU beds, childrenshospital, resident 





Figure 15: Adjusted kidney deceased donor donation rates by
DSA, 2006.
under age 50 years have been shown to be comparable to
those of SCDs (5), and ECD kidneys provide survival ad-
vantages for select recipients in DSAs with long waiting
times (6). At some programs, kidneys with previous excel-
lent function from selected donors with otherwise accept-
able donor profiles but with acute renal failure or kidneys
with glomerulosclerosis have been transplanted with rea-
sonable recipient outcomes (7,8). Another under-utilized
but important source of organs for transplantation is the
otherwise desirable donor with a history of high-risk be-
havior (e.g. intravenous drug abuse or unprotected sexual
behaviors) for the transmission of hepatitis C or HIV. Nu-
cleic acid testing (NAT) has been adopted in many OPOs as
an adjunct to traditional serologic testing. NAT is extremely
sensitive for active viremia and will allow safe transplanta-
tion of organs from donors with higher social and infec-
tious risks (9). Such donors may represent up to 5% of the





















Source: SRTR analysis, July 2007
Figure 16: Percent living donor
kidney transplants by transplant
center,∗ 2006.
ent benefits (10). These strategies and others appear to be
catalyzing improvements in DSA performance. Since the
first Organ Breakthrough Collaborative in 2003 and through
2006, national organ donation rates have increased 23%
and the number of transplantable organs from deceased
donors has increased by 25%.
The increases in organ availability that have resulted from
improvements in conversion rates and in organ transplant
rates per donor are highly encouraging. Meeting the needs
of wait-listed candidates and achieving and exceeding the
goals of the Collaborative will also be advanced by the
adoption of organ-specific strategies. In this regard, it is
important to realize that there exists considerable addi-
tional untapped kidney donor potential. This perspective
was first presented at the 17 February 2006 meeting in
Los Angeles (Learning Session 2) of the National Organ
Transplantation Breakthrough Collaborative by one of the
authors of this article (ABL) and formally adopted by the
Collaborative as the ’7000 Kidney Challenge’. Since then,
the initiative has been renamed the ’58 DSA Challenge’ to
reflect the perspective that while the objective of reach-
ing 7000 additional kidney transplants per year compared
with the 2006 baseline is a national goal, this target can
only be achieved if the challenge is met at the level of the
individual DSA.
The 58 DSA Challenge is based upon the observation that
DSA practices vary widely in the recovery and utilization
of kidneys from existing and primarily conventional donor
sources. Across the United States, adjusted deceased
donor kidney transplant rates vary almost 2-fold from 0.73
to 1.33 (Figure 15). Furthermore, the ratio of living donor
to deceased donor kidney transplants ranges from 4% to
81% across US kidney transplant programs (Figure 16), and
the ratio of living unrelated donor to living related donor
American Journal of Transplantation 2008; 8 (Part 2): 946–957 953
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Figure 17: Percent living unrelated
donors among all living kidney donor
transplants by transplant center,∗ 2006.
kidney transplants ranges from 0% to 71% (Figure 17).
There is disparate participation in the ECD expedited kid-
ney allocation system. In 2005, Sung et al. (11) showed
that the percentage of patients wait-listed in a DSA for an
ECD kidney ranged from 2% to 95%; the percentage of
those receiving an ECD kidney transplant among all de-
ceased donor kidney transplants in a DSA ranged from 0%
to 31%. Furthermore, an SRTR analysis showed that dis-
card rates by DSA varied more than 10-fold for non-ECD
and 14-fold for ECD deceased donor kidneys (Figure 18 and
Figure 19, respectively). In addition, few transplant centers
have established paired donation, intended-candidate do-
nation and candidate desensitization protocols. And, while
it is controversial whether pre-implantation kidney biopsies
and pulsatile perfusion practices reduce discard, use of
these practices also varies considerably across the United
States.
Taken together, these observations suggest that there now























Source: SRTR analysis, January 2005. Adjusted for donor race, sex, diabetes, DCD, creatinine 
clearance, pumping, and biopsy. 
DSA
Figure 18: Adjusted odds ratio of discard for non-ECD kidneys
by DSA, 1999–2002.
transplant programs, donor hospitals and OPOs can work
together to increase DSA-wide kidney transplantation
rates. To be optimally effective, DSAs need to maximize
their utilization of all sources of potential donor kidneys.
Small increments in several or all of the potential donor
sources enumerated above have the capacity when con-
sidered collectively to markedly increase kidney availability
for transplantation. For example, a DSA recovering only
one additional donor from each of these potential sources
per month could conceivably increase its total number of
monthly transplants by 15, i.e. one SCD (two kidneys),
one ECD (two kidneys), one DCD (two kidneys), one living-
related donor (one kidney), one living unrelated donor (one
kidney), one paired donation (two kidneys), one intended-
candidate donation (one kidney), one desensitization proto-
col for a potential living donor recipient (one kidney), one en
bloc or dual kidney transplant (one kidney transplant) and
one hepatitis C antibody or hepatitis B core antibody pos-
itive donor (two kidneys). Such a hypothetical DSA would




















Source: SRTR analysis, January 2005. Adjusted for donor race, s ex, diabetes, DCD, creatinine 
clearance, pumping, and biopsy. 
DSA
Figure 19: Adjusted odds ratio of discard for ECD kidneys by
DSA, 1999–2002.
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Source: 2007 OPTN/SRTR Annual Report, Tables 1.3 and 5.1a. Predicted values are 




Figure 20: Projected growth in the waiting list for deceased
donor kidneys, 1997–2030: with prediction of 7000 incremen-
tal transplants per year.
under consideration. The pragmatism of this suggestion
lies in the recognition of untapped potential in the overall
donor pool and in the strategy of DSAs focusing on sev-
eral sources to increase the number of kidneys available
for transplant and not limiting themselves to only one or
two mechanisms to generate all incremental transplants.
Can a DSA perform 10 more kidney transplants per month?
The answer, for many, is yes. And, while the goal of 10
extra kidney transplants per month may be beyond the
capacity of some smaller DSAs, it is certainly within the
reach of many, if not all, of the larger ones to exceed these
targets. The impact of increasing the average number of
transplants from all sources by a total of 10 per DSA is
potentially profound:
58 DSAs × 10 incremental kidney transplants =
580 incremental kidney transplants nationally/month
580 incremental kidney transplants nationally/month x
12 months =
6960 incremental kidney transplants nationally/year
Figure 20 projects the time it would take to eliminate the
kidney transplant waiting list based upon current projec-
tions for waiting list growth. Recognition that the growth in
the rate of ESRD has slowed (1) and assuming that current
rates of both growth and listing as Status 7 persist, fulfill-
ment of the 58 DSA Challenge would eliminate the active
kidney transplant waiting list by 2015. If it were to be as-
sumed that all the listed patients were transplantable, the
waiting list would disappear by 2030. Since it is likely that
a shortened waiting list would motivate more aggressive
listing practices and unlikely that all Status 7 candidates
would become active, these dates probably describe the
logical upper and lower boundaries at which resolution of
the waiting list could be achieved.
The implications of achieving the goals of the 58 DSA Chal-
lenge are immense. The duration of pre-transplant dialysis
exposure is recognized as having a significant adverse ef-
fect on posttransplant kidney allograft and patient survival.
Minimizing waiting time by increasing the donor pool may
therefore lead to better posttransplant survival by reduc-
ing the interval of pretransplant ESRD time. Furthermore,
in the 2006 SRTR Report on the State of Transplantation,
Ashby et al. reported that nationally access to the OPTN
kidney transplant waiting list varied more than 2.5-fold by
state (12). It is at least theoretically possible that a short-
ened national waiting list might lead to liberalized wait-
listing practices and new opportunity for deserving and
potentially listable candidates in areas of the country that
currently have relatively lower rates of wait-listing. Further-
more, should waiting time largely disappear, dependence
on some currently controversial donation practices (use of
ECD kidneys and of hypertensive or diabetic living donors)
and the rationale for adoption of compensated living dona-
tion may resolve.
Additionally, since 2003, the OPTN Kidney Transplanta-
tion Committee has been working to develop a deceased
donor kidney allocation system that is proposed to include,
among other elements, an estimate of the extra years of
life that a transplant candidate might achieve by receiving
a kidney transplant from a specific deceased donor com-
pared with that candidate’s expected life span on dialysis.
This estimate has been termed Life Years From Transplant,
or ‘LYFT’. Wolfe et al. provide a comprehensive summary
of the methodology used to calculate LYFT (13). It is antici-
pated that any proposal for a new kidney allocation system
incorporating LYFT will also provide allocation priority for
children and adolescents, sensitized candidates, years on
dialysis and prior living donation. Additional allocation con-
cerns including, but not limited to, predictability of time
to transplantation and incorporation of an index of donor
quality are also under consideration.
Some of the criticisms of LYFT-based allocation are predi-
cated on the concern that such a system might, by prefer-
entially allocating deceased donor kidneys to those candi-
dates with the best potential for additional posttransplant
survival, leave some older or more frail but still deserving
candidates with a reduced opportunity to receive a kidney
transplant. Elimination of the kidney transplant waiting list
would change this dialogue by providing certainty of trans-
plantation for all viable candidates. It would also foster the
opportunity for the allocation system to match those de-
ceased donor kidneys and candidates with the longest po-
tential survival, thereby reducing the rate of death with a
functioning transplant and increasing the total number of
years of life that can be achieved from the existing de-
ceased donor pool.
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Summary
During the last 10 years, the total number of candidates
on the kidney transplant waiting list at any time during the
calendar year increased by 81%. However, growth in the
number of active patients on the waiting list has slowed.
Comparing 2002 with 2006, only an additional 2989 pa-
tients were added to the active candidate list, whereas an
additional 13 000 wait-listed patients were listed in Status 7
(inactive status). From projections based upon the most re-
cent 5-year data, the total waiting list is estimated to grow
at a rate of 4138 registrations per year, while the active
waiting list is projected to increase at less than one-sixth
that rate, or 663 registrations per year.
Patient survival rates at 5 years were 90% for recipients of
living donor kidneys, 83% for non-ECD kidneys and 69%
for ECD transplants. At 5 years, the graft survival rate was
80% for living donor, 70% for non-ECD and 55% for ECD
transplants. The last 5 years have seen a small trend to-
ward improved unadjusted allograft survival for living and
deceased donor kidneys.
In contrast with the growth seen in kidney transplantation,
the number of new registrations for a pancreas transplant
and the number of such transplants have declined in recent
years. Among pancreas recipients, those with SPK trans-
plants experienced the best pancreas graft survival rates:
86% at 1 year and 54% at 10 years. Graft survival rates for
PAK and PTA recipients were similar to each other, with
1-year rates of 79% and 80%, respectively, and 10-year
rates of 29% and 27%, respectively.
In response to the ongoing shortage of deceased donor or-
gans, HRSA launched the National Organ Donation Break-
through Collaborative with the goal of increasing national
donation conversion rates to 75%. This was followed by
the National Organ Transplantation Breakthrough Collab-
orative in October 2005, with the objective of increasing
the average number of organs transplanted per donor to
3.75. The Collaborative strategy is based on the belief that
generating the will to change a specific health care system
requires the adoption of ‘stretch goals’ that render existing
work processes inadequate and require new systems be
implemented for targets to be achieved. The Breakthrough
Collaboratives have also provided a framework through
which best practices can be shared among DSAs.
A principal example of a stretch goal promoted by the Or-
gan Transplantation Breakthrough Collaborative is the 58
DSA Challenge. The premise of the challenge is simple. If
each of the 58 existing DSAs were to increase the number
of kidney transplants performed within their boundaries
by only 10 per month, an extra 7000 transplants per year
(over current levels) would be accomplished nationally; this
would represent an increment in kidney transplantation of
greater than 40%. Such an increase could potentially re-
duce the active national kidney transplantation waiting list
to zero within the next 10 to 20 years. The Breakthrough
Collaboratives are providing the transplant community with
a forum and a framework to foster improvement in organ
donation rates and to meet the transplantation needs of
patients with ESRD.
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